Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease

Fanni A. Boros, P. Klivényi, J. Toldi, L. Vécsei

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder. Despite the severe motor, psychiatric and cognitive symptoms and the great socioeconomic burden caused by the disease, available treatment is mainly symptomatic. The kynurenine pathway (KP) is the main metabolic route of tryptophan degradation, in the course of which several neuroactive compounds are generated. The imbalance of the neurotoxic and neuroprotectant metabolites can lead to excitotoxicity and overproduction of reactive oxygen species, which both contribute to the progression of HD. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme of the KP that has various immune modulatory roles. Areas covered: Current knowledge of the involvement of KP in HD pathogenesis with a particular focus on IDO1. By reviewing the diverse roles of the enzyme in kynurenine production, immune modulation, and serotonin metabolism, we elucidate the factors that make this enzyme a therapeutic target. Expert opinion: Due to the complexity of HD and the various effects that IDO1 exerts, targeting this enzyme, while highly profitable, may be a great challenge. Through IDO1 activity, neurodegeneration, inflammatory processes and depressive symptoms, often related to HD, can be modulated. Ongoing trials of IDO1 inhibitors in other areas of medicine offer advantages for initiating approaches toward this enzyme as a therapeutic target.

Original languageEnglish
Pages (from-to)39-51
Number of pages13
JournalExpert Opinion on Therapeutic Targets
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2 2019

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Huntington Disease
Kynurenine
Enzymes
Therapeutics
Neurobehavioral Manifestations
Expert Testimony
Neuroprotective Agents
Tryptophan
Neurodegenerative Diseases
Psychiatry
Metabolites
Reactive Oxygen Species
Serotonin
Metabolism
Medicine
Depression
Modulation
Degradation

Keywords

  • 3-dioxygenase
  • depression
  • excitotoxicity
  • Huntington’s disease
  • IDO1
  • indoleamine 2
  • inflammation
  • kynurenine pathway

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease. / Boros, Fanni A.; Klivényi, P.; Toldi, J.; Vécsei, L.

In: Expert Opinion on Therapeutic Targets, Vol. 23, No. 1, 02.01.2019, p. 39-51.

Research output: Contribution to journalArticle

@article{4e98d5ec3bd147eb9d35f77497a0f7aa,
title = "Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease",
abstract = "Introduction: Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder. Despite the severe motor, psychiatric and cognitive symptoms and the great socioeconomic burden caused by the disease, available treatment is mainly symptomatic. The kynurenine pathway (KP) is the main metabolic route of tryptophan degradation, in the course of which several neuroactive compounds are generated. The imbalance of the neurotoxic and neuroprotectant metabolites can lead to excitotoxicity and overproduction of reactive oxygen species, which both contribute to the progression of HD. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme of the KP that has various immune modulatory roles. Areas covered: Current knowledge of the involvement of KP in HD pathogenesis with a particular focus on IDO1. By reviewing the diverse roles of the enzyme in kynurenine production, immune modulation, and serotonin metabolism, we elucidate the factors that make this enzyme a therapeutic target. Expert opinion: Due to the complexity of HD and the various effects that IDO1 exerts, targeting this enzyme, while highly profitable, may be a great challenge. Through IDO1 activity, neurodegeneration, inflammatory processes and depressive symptoms, often related to HD, can be modulated. Ongoing trials of IDO1 inhibitors in other areas of medicine offer advantages for initiating approaches toward this enzyme as a therapeutic target.",
keywords = "3-dioxygenase, depression, excitotoxicity, Huntington’s disease, IDO1, indoleamine 2, inflammation, kynurenine pathway",
author = "Boros, {Fanni A.} and P. Kliv{\'e}nyi and J. Toldi and L. V{\'e}csei",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/14728222.2019.1549231",
language = "English",
volume = "23",
pages = "39--51",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease

AU - Boros, Fanni A.

AU - Klivényi, P.

AU - Toldi, J.

AU - Vécsei, L.

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Introduction: Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder. Despite the severe motor, psychiatric and cognitive symptoms and the great socioeconomic burden caused by the disease, available treatment is mainly symptomatic. The kynurenine pathway (KP) is the main metabolic route of tryptophan degradation, in the course of which several neuroactive compounds are generated. The imbalance of the neurotoxic and neuroprotectant metabolites can lead to excitotoxicity and overproduction of reactive oxygen species, which both contribute to the progression of HD. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme of the KP that has various immune modulatory roles. Areas covered: Current knowledge of the involvement of KP in HD pathogenesis with a particular focus on IDO1. By reviewing the diverse roles of the enzyme in kynurenine production, immune modulation, and serotonin metabolism, we elucidate the factors that make this enzyme a therapeutic target. Expert opinion: Due to the complexity of HD and the various effects that IDO1 exerts, targeting this enzyme, while highly profitable, may be a great challenge. Through IDO1 activity, neurodegeneration, inflammatory processes and depressive symptoms, often related to HD, can be modulated. Ongoing trials of IDO1 inhibitors in other areas of medicine offer advantages for initiating approaches toward this enzyme as a therapeutic target.

AB - Introduction: Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder. Despite the severe motor, psychiatric and cognitive symptoms and the great socioeconomic burden caused by the disease, available treatment is mainly symptomatic. The kynurenine pathway (KP) is the main metabolic route of tryptophan degradation, in the course of which several neuroactive compounds are generated. The imbalance of the neurotoxic and neuroprotectant metabolites can lead to excitotoxicity and overproduction of reactive oxygen species, which both contribute to the progression of HD. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key enzyme of the KP that has various immune modulatory roles. Areas covered: Current knowledge of the involvement of KP in HD pathogenesis with a particular focus on IDO1. By reviewing the diverse roles of the enzyme in kynurenine production, immune modulation, and serotonin metabolism, we elucidate the factors that make this enzyme a therapeutic target. Expert opinion: Due to the complexity of HD and the various effects that IDO1 exerts, targeting this enzyme, while highly profitable, may be a great challenge. Through IDO1 activity, neurodegeneration, inflammatory processes and depressive symptoms, often related to HD, can be modulated. Ongoing trials of IDO1 inhibitors in other areas of medicine offer advantages for initiating approaches toward this enzyme as a therapeutic target.

KW - 3-dioxygenase

KW - depression

KW - excitotoxicity

KW - Huntington’s disease

KW - IDO1

KW - indoleamine 2

KW - inflammation

KW - kynurenine pathway

UR - http://www.scopus.com/inward/record.url?scp=85057333220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057333220&partnerID=8YFLogxK

U2 - 10.1080/14728222.2019.1549231

DO - 10.1080/14728222.2019.1549231

M3 - Article

C2 - 30449219

AN - SCOPUS:85057333220

VL - 23

SP - 39

EP - 51

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -